RESUMO
Abstract The frequency of the use of drugs that act on the epidermal growth factor receptor (EGFR) is increasing, with the consequent onset of cutaneous toxicity, specifically acneiform eruption. The authors extensively review the topic, focusing on describing how these drugs can affect the skin and its appendages, that is, the pathophysiology that encompasses the cutaneous toxicity related to the use of EGFR inhibitors. In addition, it was possible to list the risk factors that may be associated with adverse effects of these drugs. Based on this recent knowledge, the authors expect to aid in the management of patients who are more vulnerable to toxicity, reduce morbidities, and improve the quality of life of patients undergoing treatment with EGFR inhibitors. Other issues related to the toxicity of EGFR inhibitors, such as the clinical aspects of the acneiform eruption grades, and other different types of cutaneous and mucosal reactions, are also included in the article.
RESUMO
The frequency of the use of drugs that act on the epidermal growth factor receptor (EGFR) is increasing, with the consequent onset of cutaneous toxicity, specifically acneiform eruption. The authors extensively review the topic, focusing on describing how these drugs can affect the skin and its appendages, that is, the pathophysiology that encompasses the cutaneous toxicity related to the use of EGFR inhibitors. In addition, it was possible to list the risk factors that may be associated with adverse effects of these drugs. Based on this recent knowledge, the authors expect to aid in the management of patients who are more vulnerable to toxicity, reduce morbidities, and improve the quality of life of patients undergoing treatment with EGFR inhibitors. Other issues related to the toxicity of EGFR inhibitors, such as the clinical aspects of the acneiform eruption grades, and other different types of cutaneous and mucosal reactions, are also included in the article.
Assuntos
Erupções Acneiformes , Antineoplásicos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Receptores ErbB , Humanos , Erupções Acneiformes/induzido quimicamente , Erupções Acneiformes/tratamento farmacológico , Antineoplásicos/efeitos adversos , Biomarcadores , Receptores ErbB/antagonistas & inibidores , Qualidade de Vida , Fatores de RiscoRESUMO
Patients with psychocutaneous disorders often refuse psychiatric intervention in their first consultations, leaving initial management to the dermatologist. The use of psychotropic agents in dermatological practice, represented by antidepressants, antipsychotics, anxiolytics, and mood stabilizers, should be indicated so that patients receive the most suitable treatment rapidly. It is important for dermatologists to be familiar with the most commonly used drugs for the best management of psychiatric symptoms associated with dermatoses, as well as to manage dermatologic symptoms triggered by psychiatric disorders.
Assuntos
Transtornos Mentais/tratamento farmacológico , Transtornos Psicofisiológicos/tratamento farmacológico , Psicotrópicos/uso terapêutico , Dermatopatias/tratamento farmacológico , Dermatopatias/psicologia , Dermatologia , Feminino , Humanos , Masculino , Fatores de RiscoRESUMO
Abstract Patients with psychocutaneous disorders often refuse psychiatric intervention in their first consultations, leaving initial management to the dermatologist. The use of psychotropic agents in dermatological practice, represented by antidepressants, antipsychotics, anxiolytics, and mood stabilizers, should be indicated so that patients receive the most suitable treatment rapidly. It is important for dermatologists to be familiar with the most commonly used drugs for the best management of psychiatric symptoms associated with dermatoses, as well as to manage dermatologic symptoms triggered by psychiatric disorders.
Assuntos
Humanos , Masculino , Feminino , Transtornos Psicofisiológicos/tratamento farmacológico , Psicotrópicos/uso terapêutico , Dermatopatias/psicologia , Dermatopatias/tratamento farmacológico , Transtornos Mentais/tratamento farmacológico , Fatores de Risco , DermatologiaRESUMO
We report a case of phaeohyphomycosis that affected the leg of a 45-year-old Brazilian man, car mechanic and renal transplanted. The direct mycological examination evidenced dematiaceous septated hyphae. The pathogenic fungal species was identified as Exophiala xenobiotica. Antifungal activity in vitro revealed terbinafine as the best antifungal. For treatment, it was chosen surgical excision of the entire lesion and used systemic itraconazole. Phaeohyphomycosis caused by Exophiala xenobiotica is extremely rare and is closely related to transplant patients.
Assuntos
Eosinofilia/patologia , Paniculite/patologia , Toxocara canis/isolamento & purificação , Toxocaríase/microbiologia , Animais , Nádegas , Pré-Escolar , Eosinofilia/complicações , Feminino , Humanos , Paniculite/complicações , Pele/patologia , Toxocaríase/complicações , Toxocaríase/diagnósticoAssuntos
Humanos , Animais , Feminino , Pré-Escolar , Criança , Paniculite/patologia , Toxocaríase/microbiologia , Toxocara canis/isolamento & purificação , Eosinofilia/patologia , Pele/patologia , Nádegas , Paniculite/complicações , Toxocaríase/complicações , Toxocaríase/diagnóstico , Eosinofilia/complicaçõesRESUMO
Incontinentia pigmenti is a rare genodermatosis in which the skin involvement occurs in all patients. Additionally, other ectodermal tissues may be affected, such as the central nervous system, eyes, hair, nails and teeth. The disease has a X-linked dominant inheritance pattern and is usually lethal to male fetuses. The dermatological findings occur in four successive phases, following the lines of Blaschko: First phase - vesicles on an erythematous base; second phase - verrucous hyperkeratotic lesions; third phase - hyperchromic spots and fourth phase - hypochromic atrophic lesions.
Assuntos
Incontinência Pigmentar/patologia , Pele/patologia , Alopecia/etiologia , Alopecia/patologia , Catarata/etiologia , Catarata/patologia , Doenças do Sistema Nervoso Central/patologia , Humanos , Incontinência Pigmentar/complicações , Masculino , Mutação , Anormalidades Dentárias/etiologia , Anormalidades Dentárias/patologiaRESUMO
Incontinentia pigmenti is a rare genodermatosis in which the skin involvement occurs in all patients. Additionally, other ectodermal tissues may be affected, such as the central nervous system, eyes, hair, nails and teeth. The disease has a X-linked dominant inheritance pattern and is usually lethal to male fetuses. The dermatological findings occur in four successive phases, following the lines of Blaschko: First phase - vesicles on an erythematous base; second phase - verrucous hyperkeratotic lesions; third phase - hyperchromic spots and fourth phase - hypochromic atrophic lesions.